Amytrx Therapeutics
2014
FOUNDED
PRIVATE
STATUS
Angel
LATEST DEAL TYPE
(Cancelled)
1
INVESTORS
Description
Developer of drugs designed to treat diseases. The company's drugs uses cell penetrating peptides to treat inflammation which is the cause of hundreds of debilitating diseases, enabling doctors to treat diseases related to inflammation.
Website
Formerly Known As
AGH Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 2207 Crestmoor Road
- Suite 101
- Nashville, TN 37215
- United States
+1 (615) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Amytrx Therapeutics’s full profile, request a free trial.
Amytrx Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Angel (individual) | 05-Sep-2017 | Cancelled | Startup | |||
| 1. Angel (individual) | 01-Jul-2016 | 00000 | 00000 | Completed | Startup |
Amytrx Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Rugosa Partners | Venture Capital | Minority | 000 0000 | 000000 0 |
Amytrx Therapeutics Executive Team (1)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Matthew Gonda Ph.D | Co-Founder, Chief Executive Officer, Board Member and President |
Amytrx Therapeutics Board Members (6)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Dennis Carlo | Amytrx Therapeutics | Board Member | 000 0000 | |
| Lawrence Greer | Amytrx Therapeutics | Board Member | 000 0000 | |
| Raymond Pirtle | Amytrx Therapeutics | Board Member | 000 0000 | |
| Thomas Andrews | Amytrx Therapeutics | Board Member | 000 0000 |
2 Former Board Members
You’re viewing 4 of 6 board members. Get the full list »